Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2020 07:00 ET | Source: Passage Bio; Invitae

Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1

PHILADELPHIA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
November 04, 2020 07:00 ET | Source: Passage Bio

Passage Bio to Report Third Quarter 2020 Financial Results on November 10, 2020

PHILADELPHIA, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
October 28, 2020 07:00 ET | Source: Passage Bio

Passage Bio’s PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe Disease

PHILADELPHIA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
October 26, 2020 07:00 ET | Source: Passage Bio

Passage Bio’s PBGM01 Receives Orphan Drug Designation from EMA for Treatment of GM1 Gangliosidosis

PHILADELPHIA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
October 13, 2020 16:30 ET | Source: Passage Bio

Passage Bio Announces Publication of Preclinical Data That Show Single Injection of Optimized AAV Vector into Cerebral Spinal Fluid Corrects Neurological Disease, Supporting Advancement of PBGM01 into Clinic

PHILADELPHIA, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
October 06, 2020 07:00 ET | Source: Passage Bio

Passage Bio to Participate in 2020 Virtual Cell & Gene Meeting on the Mesa

PHILADELPHIA, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
September 25, 2020 07:00 ET | Source: Passage Bio

Passage Bio to Participate in Upcoming October Investor Conferences

PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
September 17, 2020 07:00 ET | Source: Passage Bio

Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program

Data Show Single Injection of AAV-Granulin Gene Therapy into Central Nervous System Reverses Frontotemporal Dementia Pathology Caused by Granulin Mutations and is Well Tolerated Study Conducted by...
September 03, 2020 08:00 ET | Source: Passage Bio

Passage Bio to Participate in Citi’s 15th Annual BioPharma Virtual Conference

PHILADELPHIA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
August 13, 2020 07:00 ET | Source: Passage Bio

Passage Bio Reports Second Quarter 2020 Financial Results and Recent Business Highlights

– Submitted IND for PBGM01 Phase 1/2 trial; currently on FDA clinical hold pending additional review of proposed ICM delivery device – – Anticipate dosing first patient in PBGM01 Phase 1/2 trial in...